Europe continues to battle counterfeiters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe continues to battle counterfeiters
Governments, regulators and international agencies continue to defend against counterfeiters; in particular, the European Commission has outlined measures that may help to better regulate pharmaceutical distributors. There is still much work to be done, however, particularly when it comes to counterfeit drugs sold via the internet.


Pharmaceutical Technology Europe
Volume 21, Issue 12

References

1. IMS Health, IMS Health Market Prognosis (2009). http://www.imshealth.com/

2. European Federation of Pharmaceutical Industries and Associations, "Combating counterfeit medicines and protecting patients through a partnership approach" (2005). http://www.efpia.eu/

3. Europa, "Protecting the legal supply chain against counterfeited medicines" (2008). http://europa.eu/

4. International Narcotics Control Board, "INCB warns of counterfeit medicines flooding markets" (2007). http://www.incb.org/

5. Europe Economics, "Policies to Combat Counterfeit Medicines: Contribution to Impact Assessment" (2008). http://www.europe-economics.com/

6. Partnership for Safe Medicines, "Counterfeit Drugs in Europe" (2005). http://www.safemedicines.org/

7. European Federation of Pharmaceutical Industries and Associations, "Zero tolerance for counterfeit medicines" (2009). http://www.efpia.eu/

8. European Commission, "Summary of responses to the public consultation document on a legislative proposal to combat counterfeit medicines for human use" (2008). http://ec.europa.eu/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here